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Background. Nonadherence to antiretroviral therapy (ARVT) is an important behavioral determinant of the success of ARVT.
Nonadherence may lead to virological failure, and increases the risk of development of drug resistance. Understanding the
prevalence of nonadherence and associated factors is important to inform secondary HIV prevention efforts. Methodology/
Principal Findings. We used data from a cross-sectional interview study of persons with HIV conducted in 18 U.S. states from
2000–2004. We calculated the proportion of nonadherent respondents (took ,95% of prescribed doses in the past 48 hours),
and the proportion of doses missed. We used multivariate logistic regression to describe factors associated with
nonadherence. Nine hundred and fifty-eight (16%) of 5,887 respondents reported nonadherence. Nonadherence was
significantly (p,0.05) associated with black race and Hispanic ethnicity; age ,40 years; alcohol or crack use in the prior
12 months; being prescribed $4 medications; living in a shelter or on the street; and feeling ‘‘blue’’ $14 of the past 30 days.
We found weaker associations with having both male-male sex and injection drug use risks for HIV acquisition; being
prescribed ARVT for $21 months; and being prescribed a protease inhibitor (PI)-based regimen not boosted with ritonavir. The
median proportion of doses missed was 50%. The most common reasons for missing doses were forgetting and side effects.
Conclusions/Significance. Self-reported recent nonadherence was high in our study. Our data support increased emphasis
on adherence in clinical settings, and additional research on how providers and patients can overcome barriers to adherence.
Citation: Sullivan PS, Campsmith ML, Nakamura GV, Begley EB, Schulden J, et al (2007) Patient and Regimen Characteristics Associated with Self-
Reported Nonadherence to Antiretroviral Therapy. PLoS ONE 2(6): e552. doi:10.1371/journal.pone.0000552
INTRODUCTION
The full benefit of antiretroviral therapy (ARVT) in HIV-infected
patients requires patients to be prescribed appropriate therapy, the
virus to be sensitive to the prescribed therapy, and patients to
adhere to the prescribed regimen [1]. Evidence from clinical trials
suggests that very high levels of adherence (.95%) are required
for optimally suppressing viral load and preventing the emergence
of resistant virus [2,3]. Even among those with low CD4 counts at
the initiation of ARVT, adherence is a strong predictor of increase
in CD4 count after initiation of combination ARVT [4]. There
may also be significant public health benefits associated with
prescription of antiretroviral therapy and good adherence: on
a population basis, lower viral loads are predicted to be associated
with decreased sexual [5], perinatal [6], and injection-related [7]
transmission of HIV.
Therefore, understanding the prevalence of nonadherence, its
associated factors, and reasons for nonadherence is an important
clinical and public health goal. Behaviors, such as adherence, that
are related to HIV disease progression are measured as part of
behavioral surveillance projects conducted in the United States
[8]. Generally, behavioral surveillance systems measure behaviors
of interest in a large number of persons, but do not collect the
same depth of information on specific topics that might be
collected in smaller research studies.
Although many factors have been consistently reported to be
associated with poor adherence (reviewed by Reynolds [9] and
Ammasarri [10]), other associations are less clear. For many key
demographic factors, as well as certain social and regimen-related
factors, contradictory results appear in published literature [10].
Most recently, there have been contradictory reports as to whether
some types of ARVT regimens (e.g., non-nucleoside reverse tran-
scriptase inhibitor [NNRTI] -based regimens) may be associated
with higher levels of adherence [11–16].
Methods for studying adherence are varied. They include
electronic monitoring of access to medication bottles, examination
of pharmacy records, physician estimation, and measurement of
drug levels [17–21]. These methods are costly, however, and may
be difficult to implement in large behavioral surveillance projects.
Although self-reported adherence is subject to limitations common
to interview studies and likely overestimates adherence [18], self-
report provides a measure of adherence which generally correlates
well with more objective methods [21–26] and with virologic
treatment response [27]. It is also practical for use in ongoing
behavioral surveillance efforts. We report the results of an
exploratory analysis of behavioral surveillance data on self-
reported adherence from a multi-state supplemental surveillance
study of persons with HIV infection.
METHODS
Project
The Supplement to HIV and AIDS Surveillance (SHAS) Project is
a cross-sectional behavioral surveillance study of persons with HIV
infection. The methods have been previously described [28].
Briefly, adults, aged 18 years and older, reported with HIV or
AIDS through routine case surveillance were eligible for participa-
tion. Participants were enrolled using one of two methods: 1)
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at selected health care facilities in Denver, Colorado; Hartford and
New Haven, Connecticut; Jacksonville, Miami, and Tampa,
Florida; Atlanta, Georgia; Chicago, Illinois; Baltimore, Maryland;
Detroit, Michigan; Jersey City and Paterson, New Jersey; and
Philadelphia, Pennsylvania; or 2) population-based recruitment of
all eligible persons in Phoenix and Tucson, Arizona; Delaware;
Kansas; Los Angeles County, California; Minneapolis/St. Paul,
Minnesota; New Mexico; South Carolina; Austin and Houston,
Texas; and Washington. All sites interviewed persons reported
with AIDS. Additionally, during the time period examined for this
analysis, Arizona, Denver, Detroit, Florida, Kansas, Minnesota,
New Jersey, New Mexico, South Carolina and Texas also
interviewed persons with HIV infection which had not progressed
to AIDS. Informed consent was obtained from all participants
prior to the interview, and the study received institutional review
board (IRB) approval at both the Centers for Disease Control and
Prevention and local levels.
Measures
Beginning in May 2000, the SHAS Project added questions on
medication history, adherence, and reasons for nonadherence. We
utilized data from interviews conducted from May 2000 through
June 2004 (when the project ended). Respondents who were
prescribed antiretroviral therapy at the time of the interview were
asked, ‘‘In the last 48 hours, have you missed or skipped any pills
or spoonfuls of any of your antiretroviral medications?’’ We
collected detailed information about the prescribed antiretroviral
regimens at the time of the interview, including the number of
daily doses prescribed for each medication. For respondents who
reported missing one or more doses of medication in the 48 hours
before interview, we asked about the number of doses missed, and
calculated the total proportion of doses taken. We defined
nonadherence as taking less than 95% of prescribed doses in the
48 hours before interview. We also asked the reasons why doses
were missed and field coded the participants’ responses using a list
of possible reasons constructed by the investigators. Interviewers
received training on administering the questionnaire, and used
reference materials, including pictures of capsules of various
medications, to help respondents identify their current prescrip-
tions.
We defined protease inhibitor (PI)-based regimens as consisting
of any 2 or more nucleoside/nucleotide reverse transcriptase
inhibitors (NRTIs) plus any PI; boosted PI-based regimens as
additionally including ritonavir; unboosted PI-based regimens as
not including ritonavir; NNRTI-based regimens as consisting of
any 2 or more NRTIs plus any NNRTI; triple NRTI therapy as
consisting of any 3 or more NRTIs; and other ARVT as consisting
of any one or more PI, NNRTI, NRTI, or pentafuside, but not
meeting one of the previous definitions.
Analyses of All SHAS Respondents
We constructed a multivariate logistic regression model (PROC
LOGISTIC, SAS Institute, Cary, NC) to calculate adjusted odd
ratios and 95% confidence intervals for factors associated with
nonadherence. We selected putative explanatory variables based
on review of published biomedical literature. Our putative
explanatory variables fell into several categories: demographic
factors (age, race, sex, risk for acquiring HIV infection),
socioeconomic status indicators (living situation, income, educa-
tion, being on public assistance, and currently having health
insurance) recent substance use behaviors (use of alcohol, crack, or
injection drugs in the 12 months before the interview, and the
CAGE questions [29] for possible alcohol abuse), characteristics of
the ARVT regimen (type of regimen, number of drugs in the
regimen, and duration of ARVT treatment), aspects of HIV care
(use of a reminder system for medications, and whether the
healthcare provider had discussed antiretroviral resistance with the
patient), and indicators of depression (‘‘feeling blue’’ for $14 of the
past 30 days, having limited activity for $14 of the past 30 days,
reporting a current met or unmet need for mental health services,
and history of incarceration).
To construct our model, we first examined correlation
coefficients of all pairs of putative explanatory variables. Where
significant correlations existed, we removed one of the two
correlated variables from consideration. For example, being on
public assistance was removed from consideration, but current
income was retained for consideration. We conducted bivariate
analyses for all remaining explanatory variables, and only those
with a p value of ,0.25 from chi-square testing were considered in
subsequent model building. Next we built a multivariate logistic
regression model using manual forward selection. At each step, the
remaining variable with the largest chi-square for its association
with nonadherence was entered into the model, and inspected to
determine if the associated p value in the model was ,0.05.
Factors continued to be entered until the last factor entered had a p
value of .0.05. Once factors were entered into the model, they
were not removed. The model was complete with respect to first
order terms when no other variable could be entered and retained
with a p value of ,0.05. After all first order terms were entered
into the model, we checked all two-way interaction terms, using an
experiment-wide alpha of 0.05 because of the large number of
two-way terms tested. No significant two-way interaction term was
identified.
We conducted a similar process of modeling, in which, for
certain factors with multiple levels – race, age, risk for HIV
acquisition, ARVT regimen type, regimen duration, and number
of drugs in regimen – if any level of the factor was significant, all
levels of the factor would be retained in the model, regardless of
significance. The results of this model were essentially the same as
the reduced model, so we chose to present the reduced model.
For those who reported nonadherence, we also calculated the
proportion of doses missed in the 48 hours before the interview,
and tabulated the main reasons reported for missing doses.
Subgroup Analysis: Validation of Self-Reported
Adherence Using Viral Load Measurements
We validated our self-reported adherence outcome measure by
using data from a subset of SHAS respondents prescribed ARVT
at the time of interview who were also observed in the Adult and
Adolescent Spectrum of HIV Disease (ASD) Project (a longitudinal
medical records review project conducted in some of the same
project areas as SHAS) [30]. For those who were in both SHAS
and ASD datasets, we determined the lowest HIV RNA
concentration during the 6 month period including the SHAS
interview date for each respondent. The distributions of HIV
RNA concentration were not normal for either those who reported
nonadherence or those who did not report nonadherence.
Therefore, the median HIV RNA concentrations between the
two groups were compared using the Wilcoxon Rank Sum test.
RESULTS
From May 2000 through June 2004, 11,503 persons were offered
enrollment in SHAS; 9,088 (79%) were interviewed, and 2,415
(21%) refused to participate. Thirty-nine of 5,926 respondents who
were prescribed ARVT at the time of interview had insufficient
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in the 48 hours before the interview, and were, therefore,
excluded. Thus, for this analysis, we included 5,887 (65% of
interviewed) respondents who had complete information on
antiretroviral prescription and dosing and who reported being
prescribed at least one antiretroviral medication at the time of
interview. Out of 5,887 respondents, 520 had been interviewed in
a state where ASD was also conducted, and had data from medical
records abstractions that spanned the date of the SHAS interview.
The 520 were included in the subgroup analyses for validation of
self-reported adherence using viral loads. The characteristics of
interviewed persons, persons who were prescribed ARVT at the
time of interview and included in the analysis of nonadherence,
and persons included in the subgroup viral load analysis, are
reported in Table 1.
Analyses of All SHAS Respondents
Among all SHAS respondents prescribed at least one antiretroviral
medication at the time of the interview, 958 (16%) reported
nonadherence in the 48 hours before the interview. The results of
multivariate logistic regression (Table 2) indicated that several
groups were significantly (p,0.05) more likely to report non-
adherence: black non-Hispanic and Hispanic respondents (versus
all other races); respondents aged 18–29 or 30–39 years (versus
those aged $40 years); respondents who reported using alcohol or
crack cocaine in the past 12 months; respondents prescribed $4
medications at the time of interview (versus 1–3 medications);
respondents who had been blue for $14 of the past 30 days; and
respondents currently living in a shelter or on the street (versus all
other living situations). Respondents living in a medical facility
were less likely to report nonadherence. Several additional factors
were significantly associated with nonadherence, but had a weak
or modest strength of association and lower bounds of the 95% CI
close to 1.0. Such weak associations were observed for having both
male-male sex and injecting drug use risks for HIV acquisition
(versus all other acquisition modes); being prescribed an unboosted
PI-based regimen (versus any other regimen); and being prescribed
ARVT for $21 months (versus ,21 months).
Among the 958 persons who were nonadherent, the median
proportion of doses missed was 50% of doses. The mode of missed
doses was 100%; 226 of 958 (24%) of nonadherent respondents
reported taking no dose of medication during the previous
48 hours.
A total of 821 persons (86% of those who missed $5% of doses
in the 48 hours before the interview) reported the most important
reason that doses were missed. The most commonly reported
reasons were forgetting to take the medicine (266 respondents,
32%); side effects from the medications (152 respondents, 16%);
inability to get to the clinic or doctor for a prescription (106
respondents, 11%); and inability to fit medications into the
respondent’s schedule (84 respondents, 9%). Other reported main
reasons included, getting depressed (28 respondents, 3%); not
believing that the medications work (21 respondents, 2%); and
being on the street, in jail, or in prison (7 respondents, 1%).
Subgroup Analysis: Validation of Self-Reported
Adherence Using Viral Load Measurements
Results from the subgroup who had HIV RNA concentrations
available for analysis indicated that the HIV RNA concentration
was higher for the 64 persons who reported taking ,95% of
prescribed doses in the 48 hours before the interview (median =
400; range: undetectable – 425,000) than for the 397 persons who
took $95% of prescribed doses (median = 85; range: undetect-
able – 750,000; p = 0.03 by 2-sided Wilcoxon Rank Sum Test).
The HIV RNA measurements were taken a median of 36 days
from the interview (interquartile range, 6–78 days).
DISCUSSION
In a large, diverse group of persons living with HIV infection, we
observed a magnitude of nonadherence that poses a considerable
threat to the individual and public health benefits of ARVT.
About 1 in 6 persons interviewed in our project had missed at least
5% of their prescribed ARVT doses in the 48 hours before the
interview. Although we used a self-reported measure, the self-
reported measure of adherence was related to virologic outcome
among a subgroup of our respondents, as indicated by viral load
measurement – a relevant biological marker associated with
adherence status [27,31]. This suggests that self-report of recent
adherence was correlated with prior adherence in our respon-
dents.
Our findings provide additional data in some areas where
inconsistent or null findings have been reported in the literature.
Table 1. Characteristics of persons with HIV infection
interviewed in the Supplement to HIV and AIDS Surveillance
Project, who were prescribed antiretroviral drugs at the time
of interview, and who were included in subgroup analyses of
viral load, 18 US states, 2000–2004
......................................................................
Characteristic
All
Respondents*
N( % )
Prescribed
antiretroviral
drugs at time
of interview
n( % )
Included in
subgroup
analysis of
viral load
n( % )
Sex
Male 6421 (72) 4333 (74) 337 (73)
Female 2487 (28) 1554 (26) 124 (27)
Race
White, non-Hispanic 1983 (22) 1393 (24) 138 (30)
Black, non-Hispanic 4883 (55) 3014 (51) 221 (48)
Hispanic 1709 (19) 1262 (21) 88 (19)
Other{ 333 (4) 218 (4) 14 (3)
Age at interview (years)
18–29 1144 (13) 633 (11) 60 (13)
30–39 3232 (36) 2113 (36) 157 (34)
.=40 4532 (51) 3141 (53) 244 (53)
Risk for HIV infection
Male-male sex 3540 (40) 2480 (42) 220 (48)
Injection drug use 1377 (15) 888 (15) 66 (14)
Male-male sex and
injection drug use
724 (8) 466 (8) 46 (10)
Male-female sex 1788 (20) 1107 (19) 60 (13)
Other risks{ 1479 (17) 946 (16) 69 (15)
AIDS Diagnosis
AIDS 5545 (62) 4336 (74) 337 (73)
HIV infection, no AIDS 3241 (36) 1551 (26) 124 (27)
Undetermined 122 (1) 0 (0) 0 (0)
*Excludes 180 respondents with incomplete responses on prescription of
antiretroviral therapy
{Other races include non-Hispanic American Indian/Alaskan Native, non-
Hispanic Asian/Pacific Islander, and persons reporting multiple races.
{Other risks include blood or blood product transfusion and unknown risks.
doi:10.1371/journal.pone.0000552.t001
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adherence [10] reported that age and race had been inconsistently
associated with adherence in previously published multivariate
analyses. We report associations between adherence and both age
and race; our data agree with another recent report of higher
adherence among older persons living with HIV infection [32].
The same summary of published literature [10] identified several
factors which had not generally been associated with adherence in
the published literature. These included risk factor for HIV
infection, length of time on therapy, and number of antiretroviral
drugs. Our analysis showed statistically significant associations
with each of these factors, although for risk factor and time on
therapy, our associations were marginally significant, especially in
light of our large sample size.
Many investigators have reported lower adherence among
persons with current substance use [33–37]. In contrast, Martini et
al. [38] found that heroin, cocaine, and alcohol users were not
more likely to report nonadherence. In our data, alcohol use and
crack use, but not recent injection drug use, were associated with
nonadherence.
Depression is a factor which has also been consistently
associated with nonadherence [2,16,37,39–43]. Although we did
not have data on clinical diagnoses of depression, we included
putative explanatory variables which might be associated with
depression. For example, days of ‘‘feeling blue’’, self-identified
need for mental health services, and days of limited activity were
considered in our modeling. Despite consistent evidence of the
association between adherence and depression in the literature
and a significant association between nonadherence and higher
number of days feeling blue in our model, only 3% of our
nonadherent respondents identified getting depressed as a main
reason for missing doses.
Among respondents in our project, prescription of an unboosted
– but not a boosted – PI-based regimen, was weakly associated
with nonadherence. Weiser et al. [13] reported no difference in
adherence between patients prescribed NNRTI versus PI-based
regimens. Other researchers have reported lower adherence
among patients prescribed PI-based regimens [12,14,16], while
Glass et al. reported more nonadherence among patients
prescribed a boosted PI-based regimen [15]. If adherence is truly
higher in patients prescribed NNRTI-based regimens, it may be
explained by a lower pill burden [14,33,44]. However, our analysis
partially controlled for lower pill burden by controlling for the
number of antiretroviral medications prescribed. Alternatively,
higher adherence for those prescribed NNRTI regimens could be
explained by fewer intolerable side effects. In our data, side effects
were a commonly reported reason for missing doses among those
who were nonadherent. Further, self-perception of body changes
such as peripheral fat loss or central fat gain are associated with
lower adherence [45], and may be more common among those
taking PI-based ARVT [46].
Even if our finding of a marginal association of nonadherence
with prescription of an unboosted PI-based regimen were
confirmed by others, the clinical significance of this finding would
be unclear. Recent findings [47] suggest that viral suppression may
be maintained with less than 95% adherence for patients on
boosted PI-based regimens. If this finding is substantiated in other
settings, then future analyses of adherence and clinical guidelines
may consider having regimen-specific thresholds to define accept-
able adherence [48].
Pill burdens for patients currently on ARVT are likely to be
significantly lower now than were pill burdens at the time of our
interviews [33,44]. This is because of new formulations which
include multiple drugs in a single pill or capsule, and regimens
which require fewer prescribed doses per day.
Although the most commonly reported reason for missed
ARVT doses was forgetting to take medications, the modal
proportion of doses missed was 100%. The fact that nearly
a quarter of non-adherent respondents took no medication during
the 48 hour period suggests that, in many cases, doses are not
missed sporadically. More prolonged periods of missed doses could
represent ‘‘drug holiday’’ periods [49], periods in which patients
ran out of medication, or periods when significant side effects or
illness prevented taking any. Future work should attempt to
Table 2. Characteristics of HIV infected persons interviewed
about adherence to currently prescribed antiretroviral
therapy, number and proportion of nonadherent
respondents, and logistic regression model of factors
associated with nonadherence among 5,887 respondents to
the Supplement to HIV/AIDS Surveillance Project, 18 US
States, 2000 to 2004
......................................................................
Characteristic
No.
interviewed
No. of respond-
ents ,95%
adherence in
prior 48 hours
(%)
Adjusted
Odds Ratio
(95% CI)
Demographics
Race
Black, non-Hispanic* 3014 584 (19) 2.0 (1.6–2.4)
Hispanic* 1262 183 (15) 1.4 (1.1–1.8)
Age (years)
18–29{ 633 121 (19) 1.4 (1.2–1.8)
30–39{ 2113 361 (17) 1.3 (1.0–1.4) {
Risk for HIV infection
is male-male sex and
injection drug use1
466 87 (19) 1.3 (1.0–1.7) {
Place of residence
Medical facilityI 117 10 (9) 0.4 (0.2–0.7)
Shelter or streetI 156 47 (30) 1.8 (1.2–2.6)
Substance use in past year
Alcohol use in past year" 3573 630 (18) 1.3 (1.1–1.5)
Crack use in past year" 624 165 (26) 1.7 (1.4–2.1)
Characteristics of ARVT regimen
Duration of ARVT
treatment $21 months**
3023 521 (17) 1.2 (1.0–1.3) {
Currently prescribed $4
ARVT medications{{
704 160 (23) 1.6 (1.3–2.0)
Currently prescribed
unboosted PI-based
HAART{{
1524 282 (19) 1.2 (1.0–1.4) {
Mental Health Indicators
Felt blue 14 or more of
last 30 days
172 37 (22) 1.6 (1.4–1.8)
ARVT: antiretroviral therapy; PI: protease inhibitor; HAART: Highly active
antiretroviral therapy.
*Referent group is all other races
{Referent group is $40 years
{Confidence interval excludes 1.0; lower bound is rounded down to 1.0.
1Referent group is all other risks
IReferent group is all other places of residence
"Any use in the 12 months before the interview
**Referent group is duration of ARVT treatment ,21 months
{{Referent group is currently prescribed 1–3 drugs
{{Referent group is any other prescribed regimen
doi:10.1371/journal.pone.0000552.t002
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doses.
Our study has some important limitations. As with any
interview study, our data are subject to recall bias and social
desirability bias [50]. We believe asking about adherence in the
48 hours before the interview should minimize recall bias. Social
desirability bias should lead to under-report of poor adherence,
which has been recently confirmed [18]; this suggests that our data
represent minimum estimates of nonadherence. However, social
desirability bias has been reported not to be a major source of
error in collecting self-reported adherence data [51]. The persons
recruited and interviewed in the SHAS project are not
representative of all persons with HIV infection or AIDS in the
project areas, or in the United States.
Further, there are important factors which are likely related to
nonadherence which the SHAS interview did not collect, and
therefore could not be included in our analysis. For example, we
did not collect information on social support or isolation [52]
(other than current living arrangements [39]), beliefs about
prognosis or treatment efficacy [53,54], perceptions of body
changes [45], cognitive factors [55,56], serostatus disclosure [57],
or life stress [54,58].
These results have some relevance for clinicians and public
health officials. Based on our findings and existing treatment
guidelines [59], providers should consider that certain groups of
patients may be especially likely to benefit from support and
guidance around the importance of adherence and strategies for
improving adherence. Our data, and the data of others, support
referral to housing resources for homeless patients and referral to
appropriate treatment for alcohol abuse, crack cocaine use, and
mental health problems, either before or concurrently with
prescription of antiretroviral medications. Some other factors
associated with nonadherence among our respondents, such as
race/ethnicity and age, are likely markers for other barriers that
lead to poor adherence. Additional focused research is needed to
determine the underlying challenges to adherence for these
patients, and to develop interventions and resources to help
physicians and patients overcome these challenges.
Adherence to antiretroviral medications also has important
public health implications. Poor adherence to ARVT may be
associated with the development of drug-resistant strains of HIV.
Also, to the extent that ARVT lowers prevalent viral loads on
a population basis, there should be a desirable impact on reducing
the risk of HIV transmission. Poor adherence also compromises
this potential population-level benefit of ARVT. Thus, adherence
is a relevant behavior for targeting with interventions, and for
monitoring as a part of future behavioral surveillance projects
[60]. Although large-scale behavioral surveillance efforts are not
designed to provide detailed clinical information about adherence
and its consequences, and are subject to some important
limitations, such systems offer the opportunity to measure
important variables related to HIV care, including adherence, in
an ongoing and systematic way.
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